sgp130 in Chronic Human Liver Disease

Chronic liver disease are characterized by increased levels of plasma IL-6, but the bioactivity of this cytokine in this disease is not well known. IL-6 receptor complex is regulated by multiple receptors subunits: the soluble form of IL-6 Receptor enhance IL-6 signal by a process called trans-signaling on cells expressing few membrane IL-6 receptors. Soluble gp130 is the natural inhibitor of IL-6 trans-signaling. The aim of this study is to characterize circulating and liver levels of theses compounds of IL-6 receptor complex, to unravel the bioactivity of IL-6 in this disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alcoholic Liver Disease Alcohol-Induced Disorders Alcohol-Related Disorders Chemically-Induced Disorders Chronic Hepatitis C Virus Infection Digestive System Diseases Liver Diseases Liver Diseases, Alcoholic Substance-Related Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hopital Erasme - Dpt of Gastroenterology

Brussels, 1070, Belgium

About this study

Consecutive patients undergoing transjugular liver biopsies for alcoholic liver disease or hepatitis C virus infection will be included in the study to measure plasma cytokines levels, peripheral blood mononuclear cells cytokine release and liver IL-6R compounds mRNA levels.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Alcohol excess intake and suspected liver disease
Alcohol excess intake and clinical liver cirrhosis
chronic hepatitis C virus infection and suspected liver disease
chronic hepatitis C virus infection and clinical liver cirrhosis

Exclusion criteria

other (superimposed) liver disease

Sponsors and collaborators

Lead sponsor

Erasme University Hospital

Other

Registry information

Official study title

Study of IL-6 Transsignaling in Chronic Human Liver Disease

Important dates

Study start: 2005
Primary completion: 2007
Study completion: 2008
First posted: Oct 9, 2008
Registry last updated: Oct 9, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed